Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 3/20 | 0.39 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430327 | 0.80 | TRPA1 (0.42) | METTRPA1DRD1IDO1METAP2 | |
| SCHEMBL13745163 | 0.79 | NOS1 (0.46) | METTRPA1DRD1IDO1METAP2 | |
| SCHEMBL2861366 | 0.79 | TRPA1 (0.44) | METTRPA1DRD1IDO1METAP2 | |
| SCHEMBL4141136 | 0.78 | BRD4 (0.43) | METTRPA1DRD1IDO1METAP2 | |
| SCHEMBL27051452 | 0.78 | MET (0.39) | METTRPA1DRD1IDO1METAP2 | |
| SCHEMBL8404436 | 0.75 | IDO1 (0.46) | TRPA1IDO1METAP2NOS1AXL | |
| SCHEMBL2427200 | 0.75 | AXL (0.46) | METTRPA1METAP2AXL | |
| SCHEMBL18056562 | 0.75 | MET (0.42) | METIDO1METAP2NOS1AXL | |
| SCHEMBL30751781 | 0.74 | NOS1 (0.53) | METTRPA1IDO1METAP2NOS1 | |
| SCHEMBL457549 | 0.74 | NOS1 (0.53) | METTRPA1IDO1METAP2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007058626-A1 | INDAZOLE COMPOUNDS | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | MET 1502/4885TRPA1 4808/4885DRD1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.